AbbVie stock target cut, keeps Buy rating on growth outlook
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.
AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
MM&M17h
Skyrizi claims year-end TV ad crown among Rx, OTC pharma brands
Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.
Healio22h
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...